Clinical trial NCT01270386: A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
Official title: A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase II Study of Apatinib as Third Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Non-Small-Cell Lung Cancer
Keywords: NSCLC
apatinib
phase II
lung
cancer
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Sun Yat-sen University
First posted: 2011-01-05
Enrollment: 136
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival compared with placebo in patients with advanced non-squamous and non-small cell lung cancer who failed two lines of chemotherapy.


Eligibility criteria: Inclusion Criteria:

* ≥ 18 and ≤ 70 years of age
* Histologically or cytologic confirmed advanced non-squamous and non-small cell lung cancer.
* At least one measurable lesion which has not received radiotherapy (larger than 10 mm in diameter by spiral CT scan)
* Have failed for 2 lines of chemotherapy including EGFR-TKI.
* ECOG performance scale 0 - 1.
* Life expectancy of more than 3 months.
* Duration from the last therapy is more than 6 weeks for nitroso or mitomycin
* More than 4 weeks after operation or radiotherapy
* More than 4 weeks for cytotoxic agents or tyrosine kinase inhibitors inhibitors
* Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/L, platelets ≥ 80×10\^9/L, neutrophils ≥ 1.5×10\^9/L, total bilirubin within 1.25×the upper limit of normal(ULN), and serum transaminase≤2.5×the ULN (If liver metastases, serum transaminase≤5×the ULN), serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥ 50ml/min,
* signed and dated informed consent.Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.

Exclusion Criteria:

* Squamous cell carcinoma (including adenosquamous carcinoma, undifferentiated carcinoma); small cell lung cancer (including small cell and non-small cell mixed lung cancer)
* Pregnant or breastfeeding women
* Intercurrence with one of the following: hypertension, coronary artery disease, arrhythmia and heart failure
* Any factors that influence the usage of oral administration
* PT, APTT, TT, Fbg abnormal, Receiving the therapy of thrombolysis or anticoagulation.
* Within 4 weeks before the first use of drugs, occurs pulmonary hemorrhage (≥ CTCAE class 2) or other parts' hemorrhage (≥ CTCAE class 3).
* Long-term untreated wounds or fractures.
* Within 6 months before the first treatment occurs artery / venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism, etc.
* Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogues; If the prothrombin time international normalized ratio (INR) ≤ 1.5, with the purpose of prevention, the use of small doses of warfarin (1mg orally, once daily) or low-dose aspirin (between 80mg to 100mg daily) is allowed.
* Abuse of alcohol or drugs
* Less than 4 weeks from the last clinical trial
* Treatment with VEGFR, PDGFR, sSRC-TKI before.
* History of any second malignancies within 3 years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.

Primary outcomes:
measure: Progression free survival
timeFrame: 8 weeks
Secondary outcomes:
measure: Overall Survival safety
timeFrame: 8 weeks
measure: DCR(Disease control rate)
timeFrame: 8 weeks
measure: ORR(objective response rate)
timeFrame: 8 weeks
measure: QoL(quality of life)
timeFrame: 8 weeks
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Department of Medical Oncology, Cancer Center, Sun Yet-sen University
state: Guangdong
Study officials:
affiliation: Sun Yat-sen University
name: Li Zhang, Dr
role: PRINCIPAL_INVESTIGATOR
References: